{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:36:52Z","timestamp":1782167812812,"version":"3.54.5"},"reference-count":161,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>The gut microbiota composition is important for nutrient metabolism, mucosal barrier function, immunomodulation, and defense against pathogens. Alterations in the gut microbiome can disturb the gut ecosystem. These changes may lead to the loss of beneficial bacteria or an increase in potentially pathogenic bacteria. Furthermore, these have been shown to contribute to the pathophysiology of gastrointestinal and extra-intestinal diseases. Pathologies of the liver, such as non-alcoholic liver disease, alcoholic liver disease, cirrhosis, hepatocellular carcinoma, autoimmune hepatitis, viral hepatitis, and primary sclerosing cholangitis have all been linked to changes in the gut microbiome composition. There is substantial evidence that links gut dysbiosis to the progression and complications of these pathologies. This review article aimed to describe the changes seen in the gut microbiome in liver diseases and the association between gut dysbiosis and liver disease, and finally, explore treatment options that may improve gut dysbiosis in patients with liver disease.<\/jats:p>","DOI":"10.3390\/microorganisms10051045","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:59:37Z","timestamp":1652875177000},"page":"1045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Trust Your Gut: The Association of Gut Microbiota and Liver Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Ridda","family":"Manzoor","sequence":"first","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weshah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariman","family":"Afify","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashal","family":"Memon","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Yasin","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Memon","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rustom","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Al Akeel","sequence":"additional","affiliation":[{"name":"Division of Family Medicine, Department of Health, Abu Dhabi P.O. Box 5674, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-7493","authenticated-orcid":false,"given":"Noora","family":"Alhajri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sheikh Shakhbout Medical City (SSMC), Abu Dhabi P.O. Box 11001, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jhepr.2019.04.004","article-title":"The role of the gut microbiome in chronic liver disease: The clinical evidence revised","volume":"1","author":"Schwenger","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","article-title":"Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease","volume":"20","author":"Miura","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"813204","DOI":"10.3389\/fmed.2022.813204","article-title":"Guts imbalance imbalances the brain: A review of gut microbiota association with neurological and psychiatric disorders","volume":"9","author":"Mitrea","year":"2022","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., and Mele, M.C. (2019). What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms, 7.","DOI":"10.3390\/microorganisms7010014"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fukui, H. (2019). Role of gut dysbiosis in liver diseases: What have we learned so far?. Diseases, 7.","DOI":"10.3390\/diseases7040058"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.2174\/1381612811319290011","article-title":"Gut-liver axis and microbiota in NAFLD: Insight pathophysiology for novel therapeutic target","volume":"19","author":"Miele","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"725390","DOI":"10.3389\/fmed.2021.725390","article-title":"Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases","volume":"8","author":"Bruneau","year":"2021","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","article-title":"The intestinal epithelial barrier: A therapeutic target?","volume":"14","author":"Odenwald","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","article-title":"Gut microbiota: Novel therapeutic target for nonalcoholic fatty liver disease","volume":"13","author":"Suk","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"12","author":"Albillos","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2018.03.001","article-title":"Corrigendum to \u201cTargeting the gut-liver axis in liver disease\u201d [J Hepatol 67 (2017) 1084-1103]","volume":"68","author":"Wiest","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(15)00293-5","article-title":"A comprehensive repertoire of prokaryotic species identified in human beings","volume":"15","author":"Hugon","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G84","DOI":"10.1152\/ajpgi.00118.2019","article-title":"Role of gut microbiota in liver disease","volume":"318","author":"Albhaisi","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_18","first-page":"26050","article-title":"The composition of the gut microbiota throughout life, with an emphasis on early life","volume":"26","author":"Murphy","year":"2015","journal-title":"Microb. Ecol. Health Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-018-0160-1","article-title":"Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography","volume":"24","author":"Deschasaux","year":"2018","journal-title":"Nat. Med."},{"key":"ref_20","first-page":"w14599","article-title":"New insights into the pathophysiology of inflammatory bowel disease: Microbiota, epigenetics and common signalling pathways","volume":"148","author":"Rogler","year":"2018","journal-title":"Swiss Med. Wkly"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lee, N.Y., and Suk, K.T. (2020). The role of the gut microbiome in liver cirrhosis treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010199"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrgastro.2012.156","article-title":"The role of the gut microbiota in nutrition and health","volume":"9","author":"Flint","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vallianou, N., Christodoulatos, G.S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., and Dalamaga, M. (2021). Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12010056"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"(2016). European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/hep4.1760","article-title":"Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007\u20132016","volume":"5","author":"Arshad","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12938\/bmfh.18-032","article-title":"The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms","volume":"38","author":"Jasirwan","year":"2019","journal-title":"Biosci. Microbiota Food Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7150\/ijbs.56214","article-title":"Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: Recent updates","volume":"17","author":"Khan","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1210\/en.2008-0059","article-title":"Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids","volume":"149","author":"Ge","year":"2008","journal-title":"Endocrinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","article-title":"Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: A systematic review and Meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.mib.2013.07.002","article-title":"Colonic bacterial metabolites and human health","volume":"16","author":"Russell","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"700058","DOI":"10.3389\/fnut.2021.700058","article-title":"Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents","volume":"8","author":"Tokuhara","year":"2021","journal-title":"Front. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease","volume":"157","author":"Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","article-title":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease","volume":"11","author":"Raman","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Nobili","year":"2017","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e3575","DOI":"10.1210\/clinem\/dgaa382","article-title":"Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth","volume":"105","author":"Testerman","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wong, V.W.-S., Tse, C.-H., Lam, T.T.-Y., Wong, G.L.-H., Chim, A.M.-L., Chu, W.C.-W., Yeung, D.K.-W., Law, P.T.-W., Kwan, H.-S., and Yu, J. (2013). Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis\u2014A longitudinal study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062885"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrgastro.2011.133","article-title":"The intestinal microbiota and chronic disorders of the gut","volume":"8","author":"DuPont","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40168-017-0359-2","article-title":"Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease","volume":"5","author":"Dubinkina","year":"2017","journal-title":"Microbiome"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"G966","DOI":"10.1152\/ajpgi.00380.2011","article-title":"Colonic microbiome is altered in alcoholism","volume":"302","author":"Mutlu","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.27489","article-title":"Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2016.01.003","article-title":"Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation","volume":"19","author":"Wang","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"ref_49","unstructured":"GBD 2017 Cirrhosis Collaborators (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 245\u2013266."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Krag","year":"2021","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1053\/j.gastro.2008.03.002","article-title":"Cellular and molecular mechanisms of liver injury","volume":"134","author":"Malhi","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Friedman","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies","volume":"44","author":"Pagliaro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","article-title":"Linkage of gut microbiome with cognition in hepatic encephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4254\/wjh.v13.i5.557","article-title":"Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis","volume":"13","author":"Maslennikov","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/ajg.2013.221","article-title":"Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing","volume":"108","author":"Zhang","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trsl.2016.07.005","article-title":"Gut microbiome and liver disease","volume":"179","author":"Betrapally","year":"2017","journal-title":"Transl. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: Unraveling a complex relationship","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microbes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34055","DOI":"10.1038\/srep34055","article-title":"Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","article-title":"Covert and overt hepatic encephalopathy: Diagnosis and management","volume":"13","author":"Patidar","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"26800","DOI":"10.1038\/srep26800","article-title":"Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis","volume":"6","author":"Ahluwalia","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fphys.2018.00470","article-title":"Small bowel transit and altered gut microbiota in patients with liver cirrhosis","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12000","DOI":"10.1038\/s41598-019-48352-5","article-title":"Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis","volume":"9","author":"Horvath","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","article-title":"Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis","volume":"160","author":"Guilly","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s12029-021-00748-1","article-title":"The gut microbiome and hepatocellular carcinoma","volume":"52","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: A review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mittal, S., and El-Serag, H.B. (2013). Epidemiology of hepatocellular carcinoma: Consider the population. J. Clin. Gastroenterol., 47.","DOI":"10.1097\/MCG.0b013e3182872f29"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Dhanasekaran, R., Bandoh, S., and Roberts, L.R. (2016). Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. [version 1; peer review: 4 approved]. F1000Res., 5.","DOI":"10.12688\/f1000research.6946.1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/hep.24217","article-title":"Telomerase gene mutations are associated with cirrhosis formation","volume":"53","author":"Hartmann","year":"2011","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.24173","article-title":"Constitutional telomerase mutations are genetic risk factors for cirrhosis","volume":"53","author":"Calado","year":"2011","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/0140-6736(91)92236-U","article-title":"p53 mutation in hepatocellular carcinoma after aflatoxin exposure","volume":"338","author":"Ozturk","year":"1991","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/hep.26540","article-title":"Identification of driver genes in hepatocellular carcinoma by exome sequencing","volume":"58","author":"Cleary","year":"2013","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1349-7006.2010.01549.x","article-title":"Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma","volume":"101","author":"Deng","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.22849","article-title":"Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma","volume":"121","author":"Su","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"19355","DOI":"10.18632\/oncotarget.8466","article-title":"Distinctly altered gut microbiota in the progression of liver disease","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","article-title":"Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis","volume":"48","author":"Wronka","year":"2016","journal-title":"Transplant. Proc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jhep.2012.06.011","article-title":"Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats","volume":"57","author":"Zhang","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3389\/fmicb.2019.01458","article-title":"Analysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma","volume":"10","author":"Ni","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13099-018-0281-6","article-title":"Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma","volume":"11","author":"Liu","year":"2019","journal-title":"Gut Pathog."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1002\/cam4.3045","article-title":"Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma","volume":"9","author":"Zheng","year":"2020","journal-title":"Cancer Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.18632\/oncotarget.24066","article-title":"Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice","volume":"9","author":"Yamada","year":"2018","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/oxfordjournals.jbchem.a122962","article-title":"Purification and characterization of a new hydrolase for conjugated bile acids, chenodeoxycholyltaurine hydrolase, from Bacteroides vulgatus","volume":"106","author":"Kawamoto","year":"1989","journal-title":"J. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.aohep.2018.10.003","article-title":"A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma","volume":"18","author":"Vazquez","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.hbpd.2019.01.002","article-title":"Relationship between intestinal microbial dysbiosis and primary liver cancer","volume":"18","author":"Zhang","year":"2019","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s10620-017-4675-y","article-title":"Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis","volume":"62","author":"Czaja","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/MCG.0000000000001449","article-title":"Epidemiology of Autoimmune Hepatitis (AIH) in the United States Between 2014 and 2019: A Population-based National Study","volume":"55","author":"Tunio","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000336704","article-title":"Diagnosis and treatment of autoimmune hepatitis","volume":"30","author":"Lata","year":"2012","journal-title":"Dig. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41424-018-0028-1","article-title":"Role of age in presentation, response to therapy and outcome of autoimmune hepatitis","volume":"9","author":"Biewenga","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","article-title":"Study of Health in Pomerania Genome-wide association study identifies variants associated with autoimmune hepatitis type 1","volume":"147","author":"Zwiers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"987471","DOI":"10.1155\/2012\/987471","article-title":"Epstein-barr virus as a trigger of autoimmune liver diseases","volume":"2012","author":"Rigopoulou","year":"2012","journal-title":"Adv. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis","volume":"51","author":"Talwalkar","year":"2010","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cld.798","article-title":"Genetic and environmental risk factors for autoimmune hepatitis","volume":"14","author":"Lammert","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","article-title":"Etiopathogenesis of autoimmune hepatitis","volume":"95","author":"Floreani","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Vergani","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2012.11.001","article-title":"Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis","volume":"42","author":"Ehser","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20071859","article-title":"Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection","volume":"205","author":"Holdener","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Elsherbiny, N.M., Rammadan, M., Hassan, E.A., Ali, M.E., El-Rehim, A.S.A., Abbas, W.A., Abozaid, M.A.A., Hassanin, E., and Hetta, H.F. (2020). Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients. Microorganisms, 8.","DOI":"10.3390\/microorganisms8071011"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","article-title":"Alterations of gut microbiome in autoimmune hepatitis","volume":"69","author":"Wei","year":"2020","journal-title":"Gut"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/apt.15754","article-title":"A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis","volume":"51","author":"Liwinski","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_107","first-page":"5153","article-title":"Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis","volume":"8","author":"Lin","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"728723","DOI":"10.3389\/fimmu.2021.728723","article-title":"Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR\/TFH immune imbalance and intestinal microbiota composition","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"108863","DOI":"10.1016\/j.jnutbio.2021.108863","article-title":"Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability","volume":"98","author":"Liu","year":"2021","journal-title":"J. Nutr. Biochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"569104","DOI":"10.3389\/fimmu.2020.569104","article-title":"Bifidobacterium animalis ssp. Lactis 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal Barrier and Liver Immune Cells","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fcimb.2020.00342","article-title":"Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals","volume":"10","author":"Lou","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3389\/fmicb.2017.02222","article-title":"Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00248-010-9801-8","article-title":"Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients","volume":"61","author":"Lu","year":"2011","journal-title":"Microb. Ecol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13099-016-0124-2","article-title":"Gut microbiome alterations in patients with stage 4 hepatitis C","volume":"8","author":"Aly","year":"2016","journal-title":"Gut Pathog."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/liv.13485","article-title":"Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls","volume":"38","author":"Heidrich","year":"2018","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.1840130425","article-title":"Biliary tract disease in rats with experimental small bowel bacterial overgrowth","volume":"13","author":"Lichtman","year":"1991","journal-title":"Hepatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S186097","article-title":"A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis","volume":"12","author":"Vaughn","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/cei.13397","article-title":"Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease","volume":"199","author":"Quraishi","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/acs.jproteome.8b00849","article-title":"Metabolic Signature of Primary Biliary Cholangitis and Its Comparison with Celiac Disease","volume":"18","author":"Vignoli","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00535-020-01740-5","article-title":"The gut mycobiome: A novel player in chronic liver diseases","volume":"56","author":"Jiang","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1984122","DOI":"10.1080\/19490976.2021.1984122","article-title":"Gut non-bacterial microbiota contributing to alcohol-associated liver disease","volume":"13","author":"Gao","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jhep.2021.08.003","article-title":"Intestinal virome and therapeutic potential of bacteriophages in liver disease","volume":"75","author":"Hsu","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Stasiewicz, M., Kwa\u015bniewski, M., and Karpi\u0144ski, T.M. (2021). Microbial Associations with Pancreatic Cancer: A New Frontier in Biomarkers. Cancers, 13.","DOI":"10.3390\/cancers13153784"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","article-title":"The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease","volume":"72","author":"Chu","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fcimb.2020.00201","article-title":"Overview of the potential role of malassezia in gut health and disease","volume":"10","author":"Spatz","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_131","first-page":"42","article-title":"Non-Alcoholic Fatty Liver Disease, an Overview","volume":"18","author":"Nd","year":"2019","journal-title":"Integr. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5009\/gnl18579","article-title":"The role of intestinal fungi and its metabolites in chronic liver diseases","volume":"14","author":"You","year":"2020","journal-title":"Gut Liver"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/gutjnl-2020-322470","article-title":"Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy","volume":"70","author":"Bajaj","year":"2021","journal-title":"Gut"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Castillo, V., Figueroa, F., Gonz\u00e1lez-Pizarro, K., Jopia, P., and Ibacache-Quiroga, C. (2021). Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods, 10.","DOI":"10.3390\/foods10081719"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1097\/MCG.0b013e31817f184e","article-title":"FAO Technical meeting on prebiotics","volume":"42","author":"Pineiro","year":"2008","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Horvath, A., Durdevic, M., Leber, B., di Vora, K., Rainer, F., Krones, E., Douschan, P., Spindelboeck, W., Durchschein, F., and Zollner, G. (2020). Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Nutrients, 12.","DOI":"10.3390\/nu12061874"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Mei, L., Tang, Y., Li, M., Yang, P., Liu, Z., Yuan, J., and Zheng, P. (2015). Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138078"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1743-7075-10-35","article-title":"Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats","volume":"10","author":"Hsieh","year":"2013","journal-title":"Nutr. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12602-017-9378-3","article-title":"Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats","volume":"11","author":"Liang","year":"2019","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Ferolla, S.M., Couto, C.A., Costa-Silva, L., Armiliato, G.N.A., Pereira, C.A.S., Martins, F.S., Ferrari, M.d.L.A., Vilela, E.G., Torres, H.O.G., and Cunha, A.S. (2016). Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients, 8.","DOI":"10.3390\/nu8070397"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_145","first-page":"E1306","article-title":"Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2005.11.032","article-title":"Immunomodulation and antitumor activity of kappa-carrageenan oligosaccharides","volume":"243","author":"Yuan","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/ctg.2016.44","article-title":"Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition","volume":"7","author":"Kang","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_148","first-page":"519526","article-title":"Prescribing medications in patients with decompensated liver cirrhosis","volume":"2011","author":"Amarapurkar","year":"2011","journal-title":"Int. J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Zoratti, C., Moretti, R., Rebuzzi, L., Albergati, I.V., Di Somma, A., Decorti, G., Di Bella, S., Croc\u00e8, L.S., and Giuffr\u00e8, M. (2021). Antibiotics and liver cirrhosis: What the physicians need to know. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010031"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Hassouneh, R., and Bajaj, J.S. (2021). Gut microbiota modulation and fecal transplantation: An overview on innovative strategies for hepatic encephalopathy treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020330"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/egh.10.33","article-title":"Treatment options for primary sclerosing cholangitis","volume":"4","author":"Sinakos","year":"2010","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_154","first-page":"61","article-title":"The medical management of primary sclerosing cholangitis","volume":"10","author":"Michaels","year":"2008","journal-title":"Medscape J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-020-01664-0","article-title":"Emerging therapies for PBC","volume":"55","author":"Chascsa","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: Fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/lt.24754","article-title":"Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis","volume":"23","author":"Bajaj","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.orcp.2020.08.005","article-title":"Effects of obesity reduction on transient elastography-based parameters in pediatric non-alcoholic fatty liver disease","volume":"14","author":"Isoura","year":"2020","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/MEG.0b013e3282efa40e","article-title":"The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: Results of a double-blind randomized study","volume":"19","author":"Lata","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis","volume":"39","author":"Bajaj","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"G824","DOI":"10.1152\/ajpgi.00230.2018","article-title":"Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis","volume":"315","author":"Bajaj","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/5\/1045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:14:24Z","timestamp":1760138064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/5\/1045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":161,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["microorganisms10051045"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms10051045","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}